CD177 Antibody

What is CD177 and why is it a significant target for antibody-based research?

CD177 is a cell surface glycoprotein exclusively expressed on neutrophils that belongs to the Ly6 family of proteins. It is also known as NB1 or human neutrophil antigen-2 . CD177 plays an important role in the proliferation and differentiation of myeloid lineage cells including neutrophils, myelocytes, promyelocytes, megakaryocytes, and early erythroblasts in bone marrow . Recent research has identified CD177 as a novel IgG Fc receptor involved in antibody-dependent cell-mediated cytotoxicity (ADCC) .

Significantly, CD177 has been identified on specific tumor-infiltrating regulatory T cells (Treg) in various solid cancers, with the CD177+ Treg signature correlating with poorer prognosis in renal clear cell carcinoma and other solid tumors . This dual expression pattern in both neutrophils and certain Treg populations makes CD177 an attractive target for immunotherapeutic approaches and biomarker studies.

How should researchers detect CD177 expression in different cell populations?

Detection of CD177 requires methodologically sound approaches depending on the cell population being studied:

For flow cytometric analysis:

• Use validated anti-CD177 monoclonal antibodies such as MEM-166

• Analyze neutrophils in fresh blood samples to avoid expression changes during storage

• Include appropriate isotype controls

• Consider using dual staining with FOXP3 when investigating CD177+ Treg cells

For immunohistochemistry:

• Validated protocols show CD177 protein is expressed in neutrophils with polymorphic nuclei

• CD177 can also be detected in epithelial cells from colon, breast, and prostate tissues

• For detecting CD177+ Tregs, dual-color IHC with FOXP3 and CD177 antibodies is recommended

Important methodological note: When analyzing human samples, researchers should be aware that approximately 1-10% of humans are CD177 null due to genetic variants, which may impact experimental design and interpretation .

What controls should be included when validating CD177 antibody specificity?

Proper validation of CD177 antibody specificity requires multiple controls:

• Positive control: Include neutrophils from known CD177+ individuals

• Negative control: Include cells from CD177 null individuals (1-10% of the population)

• Epitope-blocking control: Pre-treatment with unconjugated anti-CD177 should block subsequent staining with conjugated antibody

• Enzymatic treatment control: Treatment with phosphatidylinositol-specific phospholipase C (PI-PLC) should remove CD177 from the cell surface, abolishing antibody binding

• Cross-reactivity testing: Test antibody against recombinant CD177 versus native CD177/PR3 complex to ensure epitope specificity

Research has shown that cleavage of CD177 from cell surface with PI-PLC and treatment with anti-CD177 monoclonal antibody both inhibit the binding of CD177 to human IgG, which can serve as functional validation of antibody specificity .

What is the significance of CD177 heterogeneity in human samples and how does it affect antibody studies?

CD177 expression exhibits significant heterogeneity in human populations:

• Most individuals have both CD177pos and CD177neg neutrophil populations

• 1-10% of individuals are CD177 null, placing them at risk for forming anti-neutrophil antibodies

• The proportion of CD177hi neutrophils in blood is a heritable trait

This heterogeneity arises from ectopic allelic conversion, where exon 7 of CD177 is partially or completely supplied by the CD177 pseudogene (CD177P1), resulting in a premature stop codon in CD177 null individuals .

Methodological implications for researchers:

• Always characterize the CD177 expression profile of samples before antibody-based experiments

• Consider genetic screening for CD177 null phenotype in immune response studies

• When using CD177 antibodies for sorting or functional studies, be aware that responses may vary based on genetic background of donors

How can researchers distinguish between different types of CD177-reactive antibodies?

Three types of antibodies target CD177, each with distinct characteristics that require specific detection methods:

Research shows that CD177 autoantibodies and isoantibodies have distinctly different binding characteristics, which is crucial for designing appropriate detection strategies .

How does CD177's newfound role as an IgG Fc receptor impact immunological research approaches?

The recent identification of CD177 as a novel IgG Fc receptor opens new research avenues:

CD177 functions as a low-affinity IgG receptor with unique characteristics compared to classical Fc receptors:

• Binding affinity (KD between 2.97×10⁻⁵ and 4.12×10⁻⁵ M) is lower than classical low-affinity IgG Fc receptors (KD between 10⁻⁶ to 10⁻⁷)

• Binds all IgG subclasses with similar affinity, unlike classical FcγRs

• Cell surface density dramatically affects interaction with IgGs

Methodological implications for researchers:

• When studying antibody-mediated effector functions, consider CD177's contribution alongside classical FcγRs

• Design experiments to account for CD177 genetic variants, which significantly affect binding capacity for human IgG and ADCC function

• Consider CD177 as a potential confounder in Fc receptor studies using neutrophils

• For studying CD177-IgG interactions, quantitative flow cytometry with escalating concentrations of human IgG can be used to characterize binding kinetics

What experimental approaches should be used to study CD177's role in tumor-infiltrating regulatory T cells?

Research has identified CD177 as specifically expressed on a subpopulation of tumor-infiltrating Treg cells with a distinct transcriptional fate (Fate-1) that correlates with poor prognosis in several solid cancers .

Recommended experimental approaches:

• Single-cell RNA sequencing to identify distinct transcriptional profiles of TI-Treg cells (as demonstrated in renal clear cell carcinoma)

• Multi-parameter flow cytometry using CD177 in combination with Treg markers (CD4, CD25, FOXP3) and activation/exhaustion markers

• Functional suppression assays comparing CD177+ vs. CD177- Treg populations

• Mouse models with Treg-specific deletion of CD177 to assess impact on tumor growth and TI-Treg frequency

Research has shown that blocking CD177 reduces the suppressive activity of Treg cells in vitro, while Treg-specific deletion of Cd177 leads to decreased tumor growth and reduced TI-Treg frequency in mice . These findings suggest CD177 as a potential target for TI-Treg-specific immunotherapy.

How should researchers address experimental challenges when CD177 stimulation fails to induce expression in in vitro systems?

Studies have reported challenges in inducing CD177 expression in peripheral blood Treg cells or conventional T cells (Tconv) under standard activation conditions:

• Human PB Treg cells from breast cancer patients failed to express CD177 after treatment with anti-CD3/CD28 and IL-2

• Splenic Treg cells from MC38 tumor-bearing mice similarly failed to express CD177 after stimulation

• CD44+CD45RA- and CD44+CD45RA+ CD4 Tconv cells also did not express CD177 after induction

Methodological solutions:

• Instead of attempting in vitro induction, isolate naturally occurring CD177+ cells from tumor tissue

• Consider using tumor-conditioned media to mimic the tumor microenvironment

• Employ co-culture systems with other cells from the tumor microenvironment

• Use genetic approaches (e.g., forced expression) when studying functional aspects of CD177

• Consider that epigenetic modifications may be necessary for CD177 expression in certain cell types

What are the methodological considerations when using CD177 antibodies to study antibody-dependent cell-mediated cytotoxicity (ADCC)?

Recent research has established CD177 as a functional receptor capable of mediating ADCC, with genetic variants significantly affecting this function .

Key methodological considerations:

• Cell model selection:

  • 293 cells expressing CD177 have been validated for studying CD177-mediated ADCC

  • NK cells have been used as effector cells in CD177 ADCC assays, though this may not fully represent physiological conditions

• Controls to establish CD177 specificity:

  • Include CD177-negative controls (vector-transfected cells)

  • Use PI-PLC treatment to remove GPI-anchored CD177 from cell surface

  • Employ blocking experiments with anti-CD177 mAbs

• Accounting for genetic variability:

  • Genotype test subjects for CD177 variants that affect IgG binding

  • Compare ADCC efficiency between cells expressing different CD177 variants

  • Consider potential interaction with classical FcγRs in experimental design

• Quantification methods:

  • Flow cytometry-based ADCC assays

  • Chromium-release or alternative non-radioactive cytotoxicity assays

  • Careful analysis of dose-response relationships with varying antibody concentrations

How can researchers reconcile contradictory data on CD177 expression and function across different disease contexts?

Research has reported seemingly contradictory findings regarding CD177's role in different pathological contexts:

Methodological approaches to reconcile these contradictions:

• Context-specific analysis: Separately analyze CD177 function in different cell types (neutrophils vs. Tregs vs. epithelial cells)

• Protein interaction studies: Identify cell-type specific binding partners that may alter CD177 function

• Signaling pathway analysis: Determine if CD177 activates different downstream pathways in different cell types

• Genetic approach: Consider that CD177 variants may exhibit tissue-specific effects

• Microenvironmental factors: Study how the tumor microenvironment may alter CD177 function

What are the prospects for developing CD177-targeted immunotherapies for cancer?

CD177's expression on tumor-infiltrating Tregs makes it a promising target for cancer immunotherapy:

• CD177 is specifically expressed on Fate-1 TI-Treg cells in several solid cancer types, but not on other TI or peripheral Treg cells

• Blocking CD177 reduces the suppressive activity of Treg cells in vitro

• Treg-specific deletion of Cd177 leads to decreased tumor growth and reduced TI-Treg frequency in mice

Methodological considerations for developing CD177-targeted therapies:

• Strategies to enhance specificity for CD177+ Tregs over neutrophils

• Potential for depleting antibodies, blocking antibodies, or bispecific approaches

• Need for comprehensive toxicity profiling given CD177's expression on neutrophils

• Consideration of CD177 null individuals in clinical trial design

• Potential for combining with existing checkpoint inhibitors

The Fate-1 TI-Treg signature (including CD177) is associated with poorer prognosis in renal clear cell carcinoma and several other solid cancers, suggesting broad therapeutic potential .

How should researchers approach CD177 as a potential biomarker in personalized medicine applications?

CD177's polymorphic expression and association with various disease outcomes positions it as a potential biomarker:

Methodological framework for CD177 biomarker development:

• Standardized detection protocols:

  • Flow cytometry with validated antibody clones for blood/bone marrow

  • Immunohistochemistry protocols for tissue samples

  • Genetic screening for CD177 variants

• Disease-specific validation studies:

  • Cancer prognosis (CD177+ TI-Tregs correlate with poorer outcomes)

  • Autoimmune conditions (CD177 autoantibodies)

  • Myeloid malignancies (altered CD177+ neutrophil percentages)

• Integration with other biomarkers:

  • Combine with other immune cell markers in multiplex assays

  • Consider ratio of CD177+ to CD177- cells within relevant populations

  • Integrate genetic data on CD177 variants

• Clinical validation pipeline:

  • Retrospective analysis in existing sample cohorts

  • Prospective observational studies

  • Correlation with treatment responses

CD177 genetic variants may serve as valuable biomarkers in antibody therapy and vaccination responses, providing insights into variable immune responses .